
## **Christian Rupp**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8525978/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impact on followâ€up strategies in patients with primary sclerosing cholangitis. Liver International, 2023, 43, 127-138.	1.9	15
2	Rapid Development of Cefiderocol Resistance in Carbapenem-resistant <i>Enterobacter cloacae</i> During Therapy Is Associated With Heterogeneous Mutations in the Catecholate Siderophore Receptor <i>cirA</i> . Clinical Infectious Diseases, 2022, 74, 905-908.	2.9	67
3	Transcriptomic Cross‧pecies Analysis of Chronic Liver Disease Reveals Consistent Regulation Between Humans and Mice. Hepatology Communications, 2022, 6, 161-177.	2.0	24
4	Predictors of Jaundice Resolution and Survival After Endoscopic Treatment of Primary Sclerosing Cholangitis. Hepatology Communications, 2022, 6, 809-820.	2.0	3
5	Obesity surgery in patients with end-stage organ failure: Is it worth it?. Surgery for Obesity and Related Diseases, 2022, 18, 495-503.	1.0	3
6	Prognostic role of selection criteria for liver transplantation in patients with hepatocellular carcinoma: a network meta-analysis. BJS Open, 2022, 6, .	0.7	6
7	Statin use is associated with the reduction in hepatocellular carcinoma recurrence after liver surgery. BMC Cancer, 2022, 22, 91.	1.1	10
8	OUP accepted manuscript. British Journal of Surgery, 2022, , .	0.1	3
9	Pregnancy with inflammatory bowel disease: Outcomes for mothers and their children at a European tertiary care center. Journal of Obstetrics and Gynaecology Research, 2022, 48, 621-633.	0.6	4
10	Balanced steady-state free precession MRCP is a robust alternative to respiration-navigated 3D turbo-spin-echo MRCP. BMC Medical Imaging, 2021, 21, 10.	1.4	3
11	Treatment stage migration and treatment sequences in patients with hepatocellular carcinoma: drawbacks and opportunities. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2471-2481.	1.2	6
12	Feasibility, effectiveness, and safety of endoscopic vacuum therapy for intrathoracic anastomotic leakage following transthoracic esophageal resection. BMC Gastroenterology, 2021, 21, 72.	0.8	16
13	HBV-infection rate and long-term outcome after liver-transplantation of anti-HBc-positive liver-grafts to HBV-naìve recipients: A retrospective study. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101496.	0.7	1
14	Programmed Death Ligand-1 (PD-L1) Is an Independent Negative Prognosticator in Western-World Gallbladder Cancer. Cancers, 2021, 13, 1682.	1.7	16
15	SARS-CoV-2 Seroprevalence and Clinical Features of COVID-19 in a German Liver Transplant Recipient Cohort: A Prospective Serosurvey Study. Transplantation Proceedings, 2021, 53, 1112-1117.	0.3	11
16	Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival. Journal of Hepatology, 2021, 74, 1362-1372.	1.8	74
17	Possible Role of the HMGB1 and RAGE Inflammatory Pathway in Primary Sclerosing Cholangitis. Clinics and Research in Hepatology and Gastroenterology, 2021, 46, 101791.	0.7	1
18	Defining Primary Sclerosing Cholangitis: Results From an International Primary Sclerosing Cholangitis Study Group Consensus Process. Gastroenterology, 2021, 161, 1764-1775.e5.	0.6	28

#	Article	IF	CITATIONS
19	Biliary calprotectin, lactoferrin and dimeric pyruvate kinase after liver transplantation are associated with biliary damage and graft survival in a case-control study. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 38-48.	0.7	2
20	Intrahepatic biliary strictures after liver transplantation are morphologically similar to primary sclerosing cholangitis but immunologically distinct. European Journal of Gastroenterology and Hepatology, 2020, 32, 276-284.	0.8	4
21	HER2 gene (ERBB2)Âamplification is a low-frequency driver with potential predictive value in gallbladder carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 871-880.	1.4	12
22	Evaluation of the impact of Tacrolimus-based immunosuppression on Heidelberg liver transplant cohort (HDTACRO). Medicine (United States), 2020, 99, e22180.	0.4	0
23	<scp>miRNA</scp> profiling of biliary intraepithelial neoplasia reveals stepwise tumorigenesis in distal cholangiocarcinoma via the <scp>miR</scp> â€451a/ <scp>ATF2</scp> axis. Journal of Pathology, 2020, 252, 239-251.	2.1	18
24	Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2020, 18, 2295-2304.e2.	2.4	18
25	Effect of mycophenolic acid on inosine monophosphate dehydrogenase (IMPDH) activity in liver transplant patients. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 543-550.	0.7	10
26	The MBOAT7 rs641738 variant is associated with an improved outcome in primary sclerosing cholangitis. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 646-652.	0.7	10
27	Evaluation of two functional CD24 polymorphisms in primary sclerosing cholangitis. Scandinavian Journal of Gastroenterology, 2020, 55, 581-587.	0.6	1
28	Alteration of the gut microbiota in patients with primary sclerosing cholangitis and concomitant dominant strictures. , 2020, 58, .		0
29	Evaluation of two functional CD24 polymorphisms in primary sclerosing cholangitis. Zeitschrift Fur Gastroenterologie, 2020, 58, .	0.2	0
30	HER2 amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis. Zeitschrift Fur Gastroenterologie, 2020, 58, .	0.2	0
31	Prevalence of human herpesviruses in biliary fluid and their association with biliary complications after liver transplantation. BMC Gastroenterology, 2019, 19, 110.	0.8	11
32	Association between serum IgG level and clinical course in primary sclerosing cholangitis. BMC Gastroenterology, 2019, 19, 153.	0.8	4
33	Longitudinal analysis of CA19â€9 reveals individualised normal range and early changes before development of biliary tract cancer in patients with primary sclerosing cholangitis. Alimentary Pharmacology and Therapeutics, 2019, 49, 769-778.	1.9	8
34	Is MRCP necessary to diagnose pancreas divisum?. BMC Medical Imaging, 2019, 19, 33.	1.4	6
35	Low frequency of mismatch repair deficiency in gallbladder cancer. Diagnostic Pathology, 2019, 14, 36.	0.9	19
36	Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis. Gut, 2019, 68, 2170-2178.	6.1	40

#	Article	IF	CITATIONS
37	Prognostic Impact of Carboxylesterase 2 in Cholangiocarcinoma. Scientific Reports, 2019, 9, 4338.	1.6	10
38	Nuclear Translocation of RELB Is Increased in Diseased Human Liver and Promotes Ductular Reaction and Biliary Fibrosis in Mice. Gastroenterology, 2019, 156, 1190-1205.e14.	0.6	19
39	Longâ€ŧerm evaluation of urinary copper excretion and non aeruloplasmin associated copper in Wilson disease patients under medical treatment. Journal of Inherited Metabolic Disease, 2019, 42, 371-380.	1.7	23
40	HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis. BMC Cancer, 2019, 19, 1191.	1.1	15
41	Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma – correlation with clinicopathological data and comparison of antibodies. BMC Cancer, 2019, 19, 72.	1.1	32
42	Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma. British Journal of Cancer, 2019, 120, 109-114.	2.9	71
43	Multidrug-Resistant Bacteria and Disease Progression in Patients with End-Stage Liver Disease and after Liver Transplantation. Journal of Gastrointestinal and Liver Diseases, 2019, 28, 303-310.	0.5	8
44	Serum miRNA-122 is an Independent Biomarker of Survival in Patients with Primary Sclerosing Cholangitis. Journal of Gastrointestinal and Liver Diseases, 2019, 27, 145-150.	0.5	8
45	The rs626283 Variant in the MBOAT7 Gene is Associated with reduced survival in primary biliary cholangitis. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.2	Ο
46	Biliary calprotectin, lactoferrin and dimeric pyruvate kinase after liver transplantation are markers for biliary damage and predict graft survival. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.2	0
47	Evaluation of serological markers of extracellular matrix remodeling in primary sclerosing cholangitis. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.2	Ο
48	Obeticholic acid for the treatment of primary biliary cholangitis – first data from a real world cohort. Zeitschrift Fur Gastroenterologie, 2019, 57, .	0.2	0
49	Impact of age at diagnosis on disease progression in patients with primary sclerosing cholangitis. United European Gastroenterology Journal, 2018, 6, 255-262.	1.6	17
50	Pathological features of primary sclerosing cholangitis identified by bile proteomic analysis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1380-1389.	1.8	21
51	Cytoplasmic localization of the cell polarity factor scribble supports liver tumor formation and tumor cell invasiveness. Hepatology, 2018, 67, 1842-1856.	3.6	48
52	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut, 2018, 67, 1517-1524.	6.1	42
53	Only the tip of the Iceberg? Role of <scp>ATP</scp> 7Bâ€exon skipping in Wilson disease. Liver International, 2018, 38, 1375-1376.	1.9	0
54	Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus. World Journal of Gastroenterology, 2018, 24, 1353-1360.	1.4	7

#	Article	IF	CITATIONS
55	Von Willebrand factor and alkaline phosphatase predict reâ€transplantationâ€free survival after the first liver transplantation. United European Gastroenterology Journal, 2017, 5, 86-93.	1.6	13
56	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology, 2017, 152, 1975-1984.e8.	0.6	355
57	Carcinoembryonic Antigen Level in Primary Sclerosing Cholangitis Is Not Influenced by Dominant Strictures or Bacterial Cholangitis. Digestive Diseases and Sciences, 2017, 62, 510-516.	1.1	7
58	Location of a biliary leak after liver resection determines success of endoscopic treatment. Surgical Endoscopy and Other Interventional Techniques, 2017, 31, 1814-1820.	1.3	13
59	Emotional Processing Theory Put to Test: A Metaâ€Analysis on the Association Between Process and Outcome Measures in Exposure Therapy. Clinical Psychology and Psychotherapy, 2017, 24, 697-711.	1.4	46
60	Novel perspectives on Wilson disease treatment. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 142, 225-230.	1.0	16
61	In PSC with dominant bile duct stenosis, multi-resistant bacteriobilia is associated with reduced survival. Zeitschrift Fur Gastroenterologie, 2017, 55, .	0.2	0
62	Evaluation of Biliary Calprotectin as a Biomarker in Primary Sclerosing Cholangitis. Medicine (United) Tj ETQq0	0 0 rgBT /C	overlock 10 Tf
63	Cardiac volume overload and pulmonary hypertension in longâ€term followâ€up of patients with a transjugular intrahepatic portosystemic shunt. Alimentary Pharmacology and Therapeutics, 2016, 43, 955-965.	1.9	44
64	Coffee consumption protects against progression in liver cirrhosis and increases longâ€ŧerm survival after liver transplantation. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1470-1475.	1.4	9
65	Microbiological Assessment of Bile and Corresponding Antibiotic Treatment. Medicine (United States), 2016, 95, e2390.	0.4	35
66	CD14 is associated with biliary stricture formation. Hepatology, 2016, 64, 843-852.	3.6	18
67	Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: A retrospective multicenter analysis. Liver Transplantation, 2016, 22, 42-52.	1.3	111
68	Genotype-Phenotype Analysis across 130,422 Genetic Variants Identifies Rspo3 as the First Genome-Wide Significant Modifier Gene in Primary Sclerosing Cholangitis. Journal of Hepatology, 2016, 64, S642-S643.	1.8	1
69	High SVR12 Rates with Combination of NS5A- and NS5B- Inhibitors for 24 Weeks in Liver Transplanted Patients. Journal of Hepatology, 2016, 64, S752.	1.8	0
70	A common genetic variant of <i>fucosyltransferase 2</i> correlates with serum carcinoembryonic antigen levels and affects cancer screening in patients with primary sclerosing cholangitis. United European Gastroenterology Journal, 2016, 4, 84-91.	1.6	17
71	Editorial: further evidence for the role of serum alkaline phosphatase as a useful surrogate marker of prognosis in <scp>PSC</scp> – authors' reply. Alimentary Pharmacology and Therapeutics, 2015, 41, 151-152.	1.9	2
72	Aggressive systemic mastocytosis of the liver with cholangitis. Hepatic Oncology, 2015, 2, 343-347.	4.2	0

Aggressive systemic mastocytosis of the liver with cholangitis. Hepatic Oncology, 2015, 2, 343-347. 72 4.2

#	Article	IF	CITATIONS
73	Criteria Used in Clinical Practice to Guide Immunosuppressive Treatment in Patients with Primary Sclerosing Cholangitis. PLoS ONE, 2015, 10, e0140525.	1.1	8
74	O076 : Cardiac volume overload and pulmonary hypertension after long-term follow-up in TIPS patients. Journal of Hepatology, 2015, 62, S228.	1.8	0
75	Inflammation But Not Biliary Obstruction Is Associated With Carbohydrate Antigen 19-9 Levels in Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 2015, 13, 2372-2379.	2.4	21
76	Association of serum zinc levels with liver function and survival in patients awaiting liver transplantation. Langenbeck's Archives of Surgery, 2015, 400, 805-811.	0.8	7
77	Risk factors and outcome in patients with primary sclerosing cholangitis with persistent biliary candidiasis. BMC Infectious Diseases, 2014, 14, 562.	1.3	31
78	<i>Fut2</i> genotype is a risk factor for dominant stenosis and biliary candida infections in primary sclerosing cholangitis. Alimentary Pharmacology and Therapeutics, 2014, 39, 873-882.	1.9	25
79	Pruritus is associated with severely impaired quality of life in patients with primary sclerosing cholangitis. European Journal of Gastroenterology and Hepatology, 2014, 26, 1374-1379.	0.8	32
80	Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis. Alimentary Pharmacology and Therapeutics, 2014, 40, 1292-1301.	1.9	88
81	Effects of Increased Von Willebrand Factor Levels on Primary Hemostasis in Thrombocytopenic Patients with Liver Cirrhosis. PLoS ONE, 2014, 9, e112583.	1.1	22
82	Body Fluid Exosomes Promote Secretion of Inflammatory Cytokines in Monocytic Cells via Toll-like Receptor Signaling. Journal of Biological Chemistry, 2013, 288, 36691-36702.	1.6	203
83	FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis. Journal of Hepatology, 2013, 59, 1278-1284.	1.8	74
84	953 FUT2 POLYMORPHISM IS ASSOCIATED WITH DOMINANT STENOSIS AND CANDIDA INFECTION IN PRIMARY SCLEROSING CHOLANGITIS. Journal of Hepatology, 2013, 58, S393.	1.8	0
85	Nonâ€ <scp>IBD</scp> immunological diseases are a risk factor for reduced survival in <scp>PSC</scp> . Liver International, 2013, 33, 86-93.	1.9	23
86	Genome-wide association analysis in Primary sclerosing cholangitis and ulcerative colitis identifies risk loci at <i>GPR35</i> and <i>TCF4</i> . Hepatology, 2013, 58, 1074-1083.	3.6	150
87	Bacteriobilia and fungibilia are associated with outcome in patients with endoscopic treatment of biliary complications after liver transplantation. Endoscopy, 2013, 45, 890-896.	1.0	35
88	A Frequent PNPLA3 Variant Is a Sex Specific Disease Modifier in PSC Patients with Bile Duct Stenosis. PLoS ONE, 2013, 8, e58734.	1.1	28
89	974 IMMUNOLOGICAL DISEASES AS A RISK FACTOR FOR SURVIVAL IN PRIMARY SCLEROSING CHOLANGITIS: INSIGHT INTO PATHOGENESIS?. Journal of Hepatology, 2012, 56, S381.	1.8	0
90	1413 A FREQUENT PNPLA3 VARIANT PREDICTS DISEASE COURSE IN PRIMARY SCLEROSING CHOLANGITIS. Journal of Hepatology, 2012, 56, S556.	1.8	2

#	Article	IF	CITATIONS
91	S100A9 is a Biliary Protein Marker of Disease Activity in Primary Sclerosing Cholangitis. PLoS ONE, 2012, 7, e29821.	1.1	29
92	CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer. Breast Cancer Research and Treatment, 2012, 132, 819-831.	1.1	21
93	1292 PSC ACTIVITY ASSESSMENT BY BILE PROTEOME ANALYSES AND CYTOLOGY. Journal of Hepatology, 2011, 54, S509.	1.8	0
94	Loss of EpCAM expression in breast cancer derived serum exosomes: Role of proteolytic cleavage. Gynecologic Oncology, 2011, 122, 437-446.	0.6	248
95	Molecular and clinical dissection of CD24 antibody specificity by a comprehensive comparative analysis. Laboratory Investigation, 2010, 90, 1102-1116.	1.7	62
96	CD24 is a marker of exosomes secreted into urine and amniotic fluid. Kidney International, 2007, 72, 1095-1102.	2.6	325
97	Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecologic Oncology, 2007, 107, 563-571.	0.6	335
98	Mnd1 Is Required for Meiotic Interhomolog Repair. Current Biology, 2004, 14, 752-762.	1.8	92
99	A screen for genes required for meiosis and spore formation based on whole-genome expression. Current Biology, 2001, 11, 1001-1009.	1.8	276